Please login to the form below

Not currently logged in
Email:
Password:

Professor Thomas Cech joins Storm Therapeutics

He takes up a scientific advisor role at the group

Thomas CechStorm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor.

Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. He currently serves on the board of directors of Merck & Co.

Commenting on the new appointments, Keith Blundy, chief executive officer of Storm Therapeutics, said: “We are very pleased to have attracted such an internationally renowned researcher as Professor Cech to Storm.

“As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be invaluable as we look to continue building a drug discovery platform and mature into a world leading therapeutics company targeting RNA epigenetic modulation.”

His new role will see him join recent hires Professor Mark Dawson and Dr Paul Leeson to boost Storm’s pipeline.

9th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics